Compare Erasca Inc. Common Stock (ERAS) vs Range Resources Corporation Common Stock (RRC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Erasca Inc. Common Stock vs Range Resources Corporation Common Stock — how do they compare? Erasca Inc. Common Stock trades at $14.6 (market cap $5.14B), while Range Resources Corporation Common Stock trades at $41.78 (market cap $9.93B). The key difference: Range Resources Corporation Common Stock is the larger of the two by market cap, and Range Resources Corporation Common Stock pays a 0.94% dividend while Erasca Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Erasca Inc. Common Stock for 1 Days and Range Resources Corporation Common Stock for 0 Days on average.
| ERAS | RRC | |
|---|---|---|
Market Cap | $5.14B | $9.93B |
Volume | 4,747,478 | 2,413,752 |
Sector | Health | Energy |
52-Week High | $22.47 | $47.65 |
52-Week Low | $2.20 | $33.43 |
Typical Hold Time | 1 Days | 0 Days |
Enterprise Value | $4.92B | $10.94B |
Dividend Yield | — | 0.94% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ERAS trades at $14.78, down 4.4% today, with a bullish technical signal from moving averages and a consensus analyst price target of $22.50. The company is a clinical-stage oncology firm with no revenue, reporting a net loss of $124.55 million in 2025, but holds significant liquidity and has three potential registration-enabling trials ahead. Recent news highlights FDA Fast Track designation for its lead candidate ERAS-0015.
The outlook is speculative, driven by clinical trial progress; upside exists if trials succeed, but high cash burn and shareholder investigations pose substantial risks. Investment hinges on binary outcomes from drug development, making it suitable only for risk-tolerant investors focused on biotech.
Range Resources (RRC) trades at $42.48, up 2.56% today, with strong earnings momentum after beating estimates for three consecutive quarters. The stock shows solid fundamentals with a P/E of 11.73 and net income margin of 26.32%, while technical indicators signal neutral momentum near key resistance at $43. Recent institutional buying and positive analyst coverage (38.71% buy ratings) support the bullish case.
Outlook remains positive with Q3 2026 earnings expected at $0.776 per share and consensus price target of $44.00 offering 3.6% upside. Risks include energy price volatility and negative net cash flow of -$304M in 2025, though improved 2026 projections show operating cash flow growth to $1.4B.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Erasca Inc. Common Stock
Erasca is a biotechnology company developing precision medicines for cancer. Its programs target genetic drivers of tumor growth.
Read more on ERAS →About Range Resources Corporation Common Stock
Range Resources Corporation is an independent natural gas and natural gas liquids producer operating in the Appalachian Basin, primarily the Marcellus Shale in Pennsylvania, handling drilling, completion, and gathering and transportation connections for its production.
Read more on RRC →
